With the advent of anti-VEGF agents, a paradigm shift occurred in the treatment of diabetic macular edema and macular edema due to retinal vein occlusion, but the treatment effect for macular edema remains unsatisfactory. This evidence concerns the gene VEGFA and diabetic macular edema.